Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic ...susceptibility.
To assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-date incidence and mortality data.
We present estimated age-standardized prostate cancer incidence and mortality rates by country and world regions for 2018 based on the GLOBOCAN database. We also examined rates and temporal trends for incidence (44 countries) and mortality (76 countries) based on data series from population-based registries.
The highest estimated incidence rates were found in Australia/New Zealand, Northern America, Western and Northern Europe, and the Caribbean, and the lowest rates were found in South-Central Asia, Northern Africa, and South-Eastern and Eastern Asia. The highest estimated mortality rates were found in the Caribbean (Barbados, Trinidad and Tobago, and Cuba), sub-Saharan Africa (South Africa), parts of former Soviet Union (Lithuania, Estonia, and Latvia), whereas the lowest rates were found in Asia (Thailand and Turkmenistan). Prostate cancer incidence rates during the most recent 5 yr declined (five countries) or stabilized (35 countries), after increasing for many years; in contrast, rates continued to increase for four countries in Eastern Europe and Asia. During the most recent 5 data years, mortality rates among the 76 countries examined increased (three countries), remained stable (59 countries), or decreased (14 countries).
As evident from available data, prostate cancer incidence and mortality rates have been on the decline or have stabilized recently in many countries, with decreases more pronounced in high-income countries. These trends may reflect a decline in prostate-specific antigen testing (incidence) and improvements in treatment (mortality).
We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates in most countries stabilized or decreased.
We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates mostly stabilized or decreased. These trends may reflect declines in prostate-specific antigen testing (incidence) and improvements in treatment (mortality).
Abstract
In this work, we investigate the far-ultraviolet (UV) to near-infrared (NIR) shape of the dust attenuation curve of a sample of IR-selected dust obscured (ultra)luminous IR galaxies at z ∼ ...2. The spectral energy distributions (SEDs) are fitted with Code Investigating GALaxy Emission, a physically motivated spectral-synthesis model based on energy balance. Its flexibility allows us to test a wide range of different analytical prescriptions for the dust attenuation curve, including the well-known Calzetti and Charlot & Fall curves, and modified versions of them. The attenuation curves computed under the assumption of our reference double power-law model are in very good agreement with those derived, in previous works, with radiative transfer (RT) SED fitting. We investigate the position of our galaxies in the IRX–β diagram and find this to be consistent with greyer slopes, on average, in the UV. We also find evidence for a flattening of the attenuation curve in the NIR with respect to more classical Calzetti-like recipes. This larger NIR attenuation yields larger derived stellar masses from SED fitting, by a median factor of ∼1.4 and up to a factor ∼10 for the most extreme cases. The star formation rate appears instead to be more dependent on the total amount of attenuation in the galaxy. Our analysis highlights the need for a flexible attenuation curve when reproducing the physical properties of a large variety of objects.
Patients with treatment-naïve metastatic urothelial carcinoma are grouped according to platinum eligibility based on clear definitions. In general, first-line treatment consists of platinum-based ...chemotherapy in which cisplatin is to be preferred to carboplatin. Patients who are cisplatin ineligible but carboplatin eligible should receive carboplatin-gemcitabine combination chemotherapy. In case of positive programmed death ligand 1 (PD-L1) status, treatment with checkpoint inhibitors (atezolizumab or pembrolizumab) could be an alternative option.
Patients unfit for both cisplatin and carboplatin (platinum unfit) can be considered for immunotherapy (U.S. Food and Drug Administration approved irrespective of PD-L1 status and European Medicines Agency approved only for PD-L1 positive) or can receive best supportive care.
Treatment of metastatic urothelial carcinoma is currently undergoing a rapid evolution.
This overview presents the updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma.
A comprehensive scoping exercise covering the topic of metastatic urothelial carcinoma is performed annually by the Guidelines Panel. Databases covered by the search included Medline, EMBASE, and the Cochrane Libraries, resulting in yearly guideline updates.
Platinum-based chemotherapy is the recommended first-line standard therapy for all patients fit to receive either cisplatin or carboplatin. Patients positive for programmed death ligand 1 (PD-L1) and ineligible for cisplatin may receive immunotherapy (atezolizumab or pembrolizumab). In case of nonprogressive disease on platinum-based chemotherapy, subsequent maintenance immunotherapy (avelumab) is recommended. For patients without maintenance therapy, the recommended second-line regimen is immunotherapy (pembrolizumab). Later-line treatment has undergone recent advances: the antibody-drug conjugate enfortumab vedotin demonstrated improved overall survival and the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib appears active in case of FGFR3 alterations.
This 2021 update of the EAU guideline provides detailed and contemporary information on the treatment of metastatic urothelial carcinoma for incorporation into clinical practice.
In recent years, several new treatment options have been introduced for patients with metastatic urothelial cancer (including bladder cancer and cancer of the upper urinary tract and urethra). These include immunotherapy and targeted treatments. This updated guideline informs clinicians and patients about optimal tailoring of treatment of affected patients.
Management of bladder cancer (BC) is primarily driven by stage, grade, and biological potential. Knowledge of each is derived using clinical, histopathological, and radiological investigations. This ...multimodal approach reduces the risk of error from one particular test, but may present a staging dilemma when results conflict. Multiparametric magnetic resonance imaging (mpMRI) may improve patient care through imaging of the bladder with better resolution of the tissue planes than computed tomography and without radiation exposure.
To define a standardized approach to imaging and reporting mpMRI for BC, by developing a VI-RADS score.
We created VI-RADS (Vesical Imaging-Reporting And Data System) through consensus using existing literature.
We describe standard imaging protocols and reporting criteria (including size, location, multiplicity, and morphology) for bladder mpMRI. We propose a five-point VI-RADS score, derived using T2-weighted MRI, diffusion-weighted imaging, and dynamic contrast enhancement, which suggests the risks of muscle invasion. We include sample images used to understand VI-RADS.
We hope that VI-RADS will standardize reporting, facilitate comparisons between patients, and in future years, will be tested and refined if necessary. While we do not advocate mpMRI for all patients with BC, this imaging may compliment pathology or reduce radiation-based imaging. Bladder mpMRI may be most useful in patients with non–muscle-invasive cancers, in expediting radical treatment or for determining response to bladder-sparing approaches.
Magnetic resonance imaging (MRI) scans for bladder cancer are becoming more common and may provide accurate information that helps improve patient care. Here, we describe a standardized reporting criterion for bladder MRI. This should improve communication between doctors and allow better comparisons between patients.
Magnetic resonance imaging (MRI) scans for bladder cancer are becoming more common and may provide accurate information that helps improve patient care. Here, we describe a standardized reporting criterion for bladder MRI. This should improve communication between doctors and allow better comparisons between patients.
Bladder cancer Kamat, Ashish M, Prof; Hahn, Noah M, MD; Efstathiou, Jason A, MD ...
The Lancet (British edition),
12/2016, Letnik:
388, Številka:
10061
Journal Article
Recenzirano
Summary Bladder cancer is a complex disease associated with high morbidity and mortality rates if not treated optimally. Awareness of haematuria as the major presenting symptom is paramount, and ...early diagnosis with individualised treatment and follow-up is the key to a successful outcome. For non-muscle-invasive bladder cancer, the mainstay of treatment is complete resection of the tumour followed by induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy. For muscle-invasive bladder cancer, multimodal treatment involving radical cystectomy with neoadjuvant chemotherapy offers the best chance for cure. Selected patients with muscle-invasive tumours can be offered bladder-sparing trimodality treatment consisting of transurethral resection with chemoradiation. Advanced disease is best treated with systemic cisplatin-based chemotherapy; immunotherapy is emerging as a viable salvage treatment for patients in whom first-line chemotherapy cannot control the disease. Developments in the past 2 years have shed light on genetic subtypes of bladder cancer that might differ from one another in response to various treatments.
HELP: the Herschel Extragalactic Legacy Project Shirley, R; Duncan, K; Campos Varillas, M C ...
Monthly notices of the Royal Astronomical Society,
10/2021, Letnik:
507, Številka:
1
Journal Article
Recenzirano
Odprti dostop
ABSTRACT
We present the Herschel Extragalactic Legacy Project (HELP). This project collates, curates, homogenizes, and creates derived data products for most of the premium multiwavelength ...extragalactic data sets. The sky boundaries for the first data release cover 1270 deg2 defined by the Herschel SPIRE extragalactic survey fields; notably the Herschel Multi-tiered Extragalactic Survey (HerMES) and the Herschel Atlas survey (H-ATLAS). Here, we describe the motivation and principal elements in the design of the project. Guiding principles are transparent or ‘open’ methodologies with care for reproducibility and identification of provenance. A key element of the design focuses around the homogenization of calibration, meta data, and the provision of information required to define the selection of the data for statistical analysis. We apply probabilistic methods that extract information directly from the images at long wavelengths, exploiting the prior information available at shorter wavelengths and providing full posterior distributions rather than maximum-likelihood estimates and associated uncertainties as in traditional catalogues. With this project definition paper, we provide full access to the first data release of HELP; Data Release 1 (DR1), including a monolithic map of the largest SPIRE extragalactic field at 385 deg2 and 18 million measurements of PACS and SPIRE fluxes. We also provide tools to access and analyse the full HELP data base. This new data set includes far-infrared photometry, photometric redshifts, and derived physical properties estimated from modelling the spectral energy distributions over the full HELP sky. All the software and data presented is publicly available.
Display omitted
•5 wt% Ni supported on Ce0.8Ti0.2O2-δ appears a very efficient “coke”-resistant DRM catalyst at 750oC.•“Carbon” deposition occurs largely via CH4 activation and to a minor extent via ...the reverse Boudouard reaction.•Surface oxygen vacant sites in Ce0.8Ti0.2O2-δ support provide an efficient alternative path for CO2 dissociation.•Ti4+ in the 20–50 atom-% range in the Ti4+-doped ceria support largely influenced carbon deposition rate”.•Ni/Ce0.8Ti0.2O2-δ shows 270 times lower amount of deposited “carbon” after 12 h of DRM at 750 oC compared to Ni/CeO2.
The carbon pathways in the dry reforming of methane with carbon dioxide (DRM) towards syngas at 750 °C have been investigated for the first time over 5 wt% Ni supported on Ti4+-doped ceria using various transient and isotopic experiments. The obtained results revealed important information about the effect of Ce1-xTixO2-δ support chemical composition (x = 0, 0.2 and 0.5) on the transient rates of “carbon” deposition via CH4/He (methane decomposition) and CO/He (Boudouard reaction), and on the rate of “carbon” removal via the participation of labile active oxygen of support under DRM reaction conditions. The alternative path of CO2 activation on the oxygen vacant sites of support was also probed by transient isothermal reduction (use of hydrogen) at 750 °C followed by transient CO2/He reaction. Quantification of the amount (mg C g−1cat) of inactive “carbon” accumulated as a function of time on stream in DRM and support chemical composition as well as of the origin of it (CH4 vs CO2 activation route), was made after conducting temperature-programmed oxidation (TPO) experiments coupled with the use of 13CO2. It was illustrated that 5 wt% Ni (dNi ∼ 20 nm) supported on Ce0.8Ti0.2O2-δ solid solution improves the H2-yield and H2/CO product gas ratio compared to 5 wt% Ni/CeO2 of similar Ni mean particle size but remarkably caused a drastic reduction in the rate of “carbon” deposition. After 12 h of DRM (20% CH4, CH4/CO2 = 1), Ni/Ce0.8Ti0.2O2-δ accumulates ∼ 270 times less “carbon” the origin of which was the CH4 activation and not the CO disproportionation route. The 5 wt% Ni/Ce0.8Ti0.2O2 catalyst developed presented high CH4 and CO2 conversions (75% and 82%), a H2-yiled of 64% and an H2/CO product gas ratio of 1.3 after 100 h of DRM at 750 °C (40%CH4/40%CO2/He; GHSV = 30,000 h−1) with a relatively low amount (73 mg “C” gcat−1 or 7.3 wt%) of inactive “carbon”, which is considered to the best of our knowledge, as one of the lowest values reported in the literature for monometallic Ni supported catalysts under the examined DRM reaction conditions.
Bladder-sparing trimodality therapy (TMT) is an alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC), and biomarkers to inform therapy selection are needed.
To evaluate ...the prognostic value of immune and stromal signatures in MIBC treated with TMT.
We used a clinical-grade platform to perform transcriptome-wide gene expression profiling of primary tumors from 136 MIBC patients treated with TMT at a single institution. We observed 60 overall survival events at 5yr, and median follow-up time for patients without an event was 5.0yr (interquartile range 3.1, 5.0). Expression data from another cohort of 223 MIBC patients treated with neoadjuvant chemotherapy (NAC) and RC were also analyzed.
Molecular subtype, immune, and stromal signatures were evaluated for associations with disease-specific survival (DSS) and overall survival (OS) in TMT patients, and in patients treated with NAC and RC.
Gene expression profiling of TMT cases identified luminal (N=40), luminal-infiltrated (N=26), basal (N=54), and claudin-low (N=16) subtypes. Signatures of T-cell activation and interferon gamma signaling were associated with improved DSS in the TMT cohort (hazard ratio 0.30 0.14–0.65, p=0.002 for T cells), but not in the NAC and RC cohort. Conversely, a stromal signature was associated with worse DSS in the NAC and RC cohort (p=0.006), but not in the TMT cohort. This study is limited by its retrospective nature.
Higher immune infiltration in MIBC is associated with improved DSS after TMT, whereas higher stromal infiltration is associated with shorter DSS after NAC and RC. Additional studies should be conducted to determine whether gene expression profiling can predict treatment response.
We used gene expression profiling to study the association between tumor microenvironment and outcomes following bladder preservation therapy for invasive bladder cancer. We found that outcomes varied with immune and stromal signatures within the tumor. We conclude that gene expression profiling has potential to guide treatment decisions in bladder cancer.
Gene expression profiling of muscle-invasive bladder cancer reveals that immune infiltration is associated with improved disease-specific survival after bladder-sparing trimodality therapy, but not after radical cystectomy. Conversely, stromal infiltration is associated with worse outcomes after cystectomy, but not after trimodality therapy.
We present the Herschel-SPIRE photometric atlas for a complete flux limited sample of 43 local ultraluminous infrared galaxies (ULIRGs), selected at 60 μm by IRAS, as part of the HERschel ULIRG ...Survey (HERUS). Photometry observations were obtained using the SPIRE instrument at 250, 350, and 500 μm. We describe these observations, present the results, and combine the new observations with data from IRAS to examine the far-infrared spectral energy distributions (SEDs) of these sources. We fit the observed SEDs of HERUS objects with a simple parametrized modified blackbody model, where temperature and emissivity β are free parameters. We compare the fitted values to those of non-ULIRG local galaxies, and find, in agreement with earlier results, that HERUS ULIRGs have warmer dust (median temperature T = 37.9 ± 4.7 K compared to 21.3 ± 3.4 K) but a similar β distribution (median β = 1.7 compared to 1.8) to the Herschel reference sample (HRS, Cortese et al. 2014) galaxies. Dust masses are found to be in the range of 107.5-109 M⊙, significantly higher than that of HRS sources. We compare our results for local ULIRGs with higher redshift samples selected at 250 and 850 μm. These latter sources generally have cooler dust and/or redder 100-to-250 μm colours than our 60 μm-selected ULIRGs. We show that this difference may in part be the result of the sources being selected at different wavelengths rather than being a simple indication of rapid evolution in the properties of the population.
Context. Dust attenuation shapes the spectral energy distribution of galaxies. It is particularly true for dusty galaxies in which stars experience a heavy attenuation. The combination of UV to IR ...photometry with the spectroscopic measurement of the Hα recombination line helps to quantify dust attenuation of the whole stellar population and its wavelength dependence. Aims. We want to derive the shape of the global attenuation curve and the amount of obscuration affecting young stars or nebular emission and the bulk of the stellar emission in a representative sample of galaxies selected in IR. We will compare our results to the commonly used recipes of Calzetti et al. and Charlot and Fall, and to predictions of radiative transfer models. Methods. We selected an IR complete sample of galaxies in the COSMOS 3D-HST CANDELS field detected with the Herschel satellite with a signal to noise ratio larger than five. Optical to NIR photometry is available as well as NIR spectroscopy for each source. We reduced the sample to the redshift range 0.6 < z < 1.6 to include the Hα line in the G141 grism spectra. We have used a new version of the CIGALE code to fit simultaneously the continuum and Hα line emission of the 34 selected galaxies. Results. Using flexible attenuation laws with free parameters, we are able to measure the shape of the attenuation curve for each galaxy as well as the amount of attenuation of each stellar population, the former being in general steeper than the starburst law in the UV-optical with a large variation of the slope among galaxies. The attenuation of young stars or nebular continuum is found on average about twice the attenuation affecting older stars, again with a large variation. Our model with power-laws, based on a modification of the Charlot and Fall recipe, gives results in better agreement with the radiative transfer models than the global modification of the slope of the Calzetti law.
PDF
